Cipla FY26 Financial Results and Strategic Updates

Financial Results for FY2026 and Q4

Cipla Limited announced its audited financial results for the fiscal year and fourth quarter ended March 31, 2026. The company reported consolidated revenue of ₹28,162.59 crore and a consolidated Profit After Tax (PAT) of ₹5,291.05 crore for FY2026. For the fourth quarter alone, consolidated PAT stood at ₹550.11 crore on revenue of ₹6,541.20 crore.

Strategic Acquisition and Dividend Recommendation

The company's Board of Directors has recommended a final dividend of ₹13 per equity share for FY2026. Cipla also confirmed the completion of its acquisition of 100% stake in Inzpera Heathscience Limited for ₹110.65 crore, alongside the approval of an amalgamation scheme.

Impairment Charges and Exceptional Items

The company recorded an impairment charge of ₹42.02 crore and an exceptional item of ₹275.91 crore. These were attributed to changing business conditions and new labor laws, impacting overall comprehensive income.

Inzpera Healthscience Integration

The acquisition of Inzpera Healthscience, which included buying the remaining 48.98% stake for ₹110.65 crore in April 2026, aligns with Cipla's strategy to expand its presence in specialized healthcare solutions. The integration is expected to bring new capabilities and revenue streams, streamlining operations between the parent company and its subsidiary.

Potential Liabilities from NPPA Notices

Cipla is facing potential liabilities from National Pharmaceutical Pricing Authority (NPPA) demand notices totaling ₹2,011 crore, related to alleged drug overcharges. The company has not made any provision for these notices, citing legal advice that anticipates a favorable outcome.

Financial Performance: Peer Comparison

In comparison to its peers for FY26, Cipla's consolidated revenue of ₹28,162.59 crore and PAT of ₹5,291.05 crore show a competitive position. Sun Pharma reported higher figures with ₹46,888 crore revenue and ₹8,700 crore PAT. Dr. Reddy's achieved similar revenue at ₹26,800 crore but a lower PAT of ₹4,400 crore. Lupin's FY26 performance was lower, with revenue at ₹17,400 crore and PAT at ₹1,600 crore.

What to Watch Next

Investors will be monitoring shareholder approval for the final dividend, the progress of the Inzpera Healthsciences amalgamation scheme, and the resolution of the NPPA demand notices. The successful integration and performance of the newly acquired Inzpera Healthscience will also be key indicators.